BERLIN and SEATTLE, Sept. 18, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic tests for cancer, announces an update on its program for the development of a prostate cancer screening and diagnostic tests. The company will present recent data at two high profile European cancer research conferences, the 35th ISOBM congress (Prague/Czech Republic) and the 14th European Cancer Conference (Barcelona/Spain).
